Dr. Judy Walker is a neurologist, board-certified in Canada and the USA, currently based in Scotland, with extensive experience and expertise across all areas of development of healthcare products for neurological indications and pain, from pre-clinical, through translational medicine, clinical development and lifecycle management. She has expertise in working with pharmaceuticals and biologics and with small, medium and large enterprises. She has also developed expertise in rare and orphan diseases.
Dr. Walker practiced Neurology in Canada where she was involved as an investigator in many clinical trials and consulted by pharmaceutical companies on drug development. In 1999, Judy joined Quintiles as Medical Director. While at Quintiles she consulted for large and mid-sized pharmaceutical companies on study design and led a Quintiles project management team with a focus on pain drug development. Between 2001 and 2004 she led the European Neurology group for Serono, working on the development of compounds in MS and other neurological disorders. She was also part of the team that prepared the regulatory package for the approval of Rebif in the US under the Orphan Drug Act. Between 2004 and 2008 she was Head of Medical Affairs for Teva Neuroscience, working on the continued development of Teva’s branded compounds, expanding their market share. In 2008 Judy returned to Quintiles, bringing her tremendous drug development experience to her role in the Global Strategic Drug Development Unit. Her role is to advise customers on how best to develop compounds into commercially successful drugs.
Dr. Walker received her Medical degree (MD) from the University of Montreal in Canada and post graduation training in Family Medicine, Internal Medicine, Intensive Care and Neurology, leading to speciality certification from the Royal College of Physicians and Surgeons of Canada and the American Board of Psychiatry and Neurology.